SAVIENT PHARMACEUTICALS INC

FORM 8-K
(Unscheduled Material Events)

Filed 6/26/2003 For Period Ending 6/23/2003

Address	ONE TOWER CENTER
	EAST BRUNSWICK, New Jersey 08816
Telephone	732-418-9300
CIK	0000722104
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

Generated by **EDGAR Online Pro**
http://pro.edgar-online.com

EDGAR Online

Contact **EDGAR Online**
Customer Service: 203-852-5666
Corporate Sales: 212-457-8200

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 23, 2003**

Savient Pharmaceuticals, Inc.

(Exact name of issuer as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation)	**0-15313** (Commission File Number)	**13-3033811** (IRS Employer Identification No.)

One Tower Center, 14 th Floor, East Brunswick, New Jersey
(Address of Principal Executive Offices)

08816
(Zip Code)

Registrant's telephone number, including area code: **(732) 418-9300**

Bio-Technology General Corp.
(Former Name or Former Address, if Changed Since Last Report.)

ITEM 9. REGULATION FD DISCLOSURE.

On June 23, 2003, Sim Fass, Chairman and Chief Executive Officer of Savient Pharmaceuticals, Inc., in various meetings held with investors following his opening of NASDAQ that day to mark the change of the name of the company from Bio-Technology General Corp. to Savient Pharmaceuticals, Inc., in response to questions, communicated the following:

The conversion of the 2.5 mg-based Oxandrin® prescriptions to 10 mg—based prescriptions is continuing and at the end of May, approximately 26% of all Oxandrin prescriptions were 10 mg—based.

Approval of a new manufacturing site for Delatestryl®, which, as previously disclosed, is SABEX in Canada, may possibly occur by year-end. Delatestryl sales for 2003 are currently projected to be approximately $9 million based on previously manufactured inventory.

The receptor to which the Company's anti-leukemic monoclonal antibody, BTG-271, binds has been identified as CD-162. This receptor is sulfated on leukemic cells but is not sulfated on normal cells. BTG-271 appears to recognize only the modified receptor.

The Company received an informal request for documents from a regional office of the S.E.C. relating to the restatement last year of the Company's financials for the years 1999, 2000, 2001 and the first half of 2002. The Company is providing requested materials.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

SAVIENT PHARMACEUTICALS, INC.
(Registrant)

By: /s/ Whitney K. Stearns, Jr.
Whitney K. Stearns, Jr.
Senior Vice President-Chief Financial Officer and Treasurer

Dated: June 26, 2003

End of Filing

Powered By EDGAR Online

© 2005 | EDGAR Online, Inc.